Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

ViiV Healthcare wins FDA nor for long-acting HIV injectable

By Brian Buntz | December 21, 2021

ViiV Healthcare

ViiV Healthcare has announced the FDA approval of Apretude (cabotegravir), which it bills as the “first and only” long-acting injectable pre-exposure prophylaxis (PrEP) option to reduce the risk of sexually acquired HIV-1.

The drug can be administered as few as six times per year.

The FDA approval covers adults and adults who weigh at least 35 kg and have a negative HIV-1 test before beginning therapy.

ViiV Healthcare is a joint venture between GlaxoSmithKline (LON:GSK), Pfizer (NYSE:PFE) and Shionogi.

“Today’s approval adds an important tool in the effort to end the HIV epidemic by providing the first option to prevent HIV that does not involve taking a daily pill,” said Dr. Debra Birnkrant, director of the Division of Antivirals in the FDA’s Center for Drug Evaluation and Research. “This injection, given every two months, will be critical to addressing the HIV epidemic in the U.S., including helping high-risk individuals and certain groups where adherence to daily medication has been a major challenge or not a realistic option,” Birnkrant said in a statement.

ViiV Healthcare also manufactures cabotegravir tablets known as Vocabria.

It plans to begin shipping Apretude in early 2022.


Filed Under: Infectious Disease

 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Skycovion
European authorities begin review of Skycovion COVID-19 vaccine candidate
Pfizer-BioNTech vaccine
U.S. government plans to stop paying for COVID-19 vaccines 
Monkeypox
U.S. to boost supplies of Tpoxx to fight monkeypox outbreak
Pfizer-BioNTech
Next-gen Pfizer-BioNTech vaccine candidates fare well in Phase 2/3 study

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50